EU regulators block new Alzheimer’s drug citing potentially fatal side effects
The company behind the drug donanemab said it will ask regulators to reconsider the decision. View on euronews ...
CHMP Recommends Against Approval of Eli Lilly's Kisunla Alzheimer's Drug -- Update
Eli Lilly, which is seeking European approval of Kisunla for the treatment of early symptomatic Alzheimer's, said it will seek re-examination by CHMP. The Indianapolis drugmaker said it remains ...
BioSpace1d
EU Rejects Lilly’s Alzheimer’s Drug Kisunla, Following Same Path as Rival Leqembi
The European Union’s CHMP said that the benefits of the drug, already approved in the U.S., do not outweigh the risk of ...
Science Daily5d
Engineering antibodies with a novel fusion protein
Even with significant expansion in the global market for antibodies used in clinical care and research, scientists recognize that there is still untapped potential for finding new antibodies. Many ...
STAT10d
Cargo Therapeutics ends development efforts
Cargo was founded by two highly acclaimed cell-therapy researchers. The company raised over $500 million to develop ...
Medical Marketing & Media2d
DTC platform LillyDirect expands to provide access for Alzheimer’s care
Eli Lilly is expanding care offerings on its direct-to-consumer (DTC) platform LillyDirect, now offering connections to ...
STAT1d
Eli Lilly’s Alzheimer’s drug gets thumbs-down from European regulators
Eli Lilly's Kisunla was approved in the U.S. for Alzheimer's last year, but now advisers to the European Medicines Agency say ...
Morningstar1d
CHMP Recommends Against Approval of Eli Lilly's Kisunla Alzheimer's Drug — Update
A key European regulatory committee has recommended against approval of Eli Lilly's Kisunla, saying the benefits of the Alzheimer's disease drug don't outweigh its risks. The European Medicines ...
Morningstar2d
CHMP Recommends Against Approval of Eli Lilly's Kisunla Alzheimer's Drug
A key European regulatory committee has recommended against approval of Eli Lilly's Kisunla, saying the benefits of the Alzheimer's disease drug don't outweigh its risks. The European Medicines ...